Immunization against a dominant tumor antigen abrogates immunogenicity ofthe tumor

Cancer Immunity

Volumn 5, Issue , 2002, Pages 1-13

  Makki, Amira ^a   Weidt, Gunnar ^a   Blachere, Nathalie E ^a,b   Lefrançois, Leo ^a   Srivastava, Pramod K ^a  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Cytotoxic T Lymphocytes; Immunization; Immunodominant epitopes; Mice; Tumor immunity

Indexed keywords

ANTIBODY; CD40 ANTIBODY; EPITOPE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; OVALBUMIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNIZATION; CONTROLLED STUDY; GENETIC TRANSFECTION; IMMUNOGENICITY; IRRADIATION; LYMPHOMA; MOUSE; NONHUMAN; PROTEIN DENATURATION; PROTEIN EXPRESSION; THYMOMA; TUMOR REJECTION; VIRUS RECOMBINANT;

EID: 3242657299     PISSN: 14249634     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Wojtowicz-Praga S. Reversal of tumor-induced immunosuppression: a new approach to cancer therapy. J Immunother 1997; 20: 165-77. (PMID: 9181454)
2. Marincola FM. The multiple ways to tumor tolerance. J Immunother 1997; 20: 178-79. (PMID: 9181455)
3. Rowley DA, Stach RM. A first or dominant immunization. I. Suppression of simultaneous cytolytic T cell responses to unrelated alloantigens. J Exp Med 1993; 178: 835-40. (PMID: 8338500)
4. Shrikant P, Mescher MF. Control of syngeneic tumor growth by activation of CD8+ T cells: efficacy is limited by migration away from the site and induction of nonresponsiveness. J Immunology 1999; 162: 2858-66. (PMID: 10072534)
5. Biddison WE, Palmer JC. Development of tumor cell resistance to syngeneic cell-mediated cytotoxicity during growth of ascitic mastocytoma P815Y. Proc Natl Acad Sci U S A 1977; 74: 329-33. (PMID: 402006)
6. Urban JL, Burton RC, Holland JM, Kripke ML, Schreiber H. Mechanisms of syngeneic tumor rejection. Susceptibility of host-selected progressor variants to various immunological effector cells. J Exp Med 1982; 155: 557. (PMID: 6977009)
7. Meeker T, Lowder J, Cleary ML, Stewart S, Warnke R, Sklar J, Levy R. Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies. New Engl J Med 1985; 312: 1658. (PMID: 3923352)
8. Flyer DC, Pretell J, Campbell AE, Liao WS, Tevethia MJ, Taylor JM. Biology of simian virus 40 (SV40) transplantation antigen (TrAg). X. Tumorigenic potential of mouse cells transformed by SV40 in high responder C57BL/6 mice and correlation with the persistence of SV40 TrAg, early proteins and sequences. Virology 1983; 131: 207-20. (PMID: 6316651)
9. Vitiello A, Yuan L, Chestnut RW, Sidney J, Southwood S, Farness P, Jackson MR, Peterson PA, Sette A. Immunodominance analysis of CTL responses to influenza PR8 virus reveals two new dominant and subdominant Kb-restricted epitopes. J Immunology 1996; 157: 5555-62. (PMID: 8955206)
10. Mylin LM, Bonneau RH, Lippolis JD, Tevethia SS. Hierarchy among multiple H-2b-restricted cytotoxic T-lymphocyte epitopes within simian virus 40 T antigen. J Virol 1995; 69: 6665-6677. (PMID: 7474076)
11. Sercarz EE, Lehmann PV, Ametani A, Benichou G, Miller A, Moudgil K. Dominance and crypticity of T cell antigenic determinants [review]. Ann Rev Immunol 1993; 11: 729-66. (PMID: 7682817)
12. Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A. Tumor antigens recognized by T lymphocytes [review]. Ann Rev Immunol 1994; 12: 337-65. (PMID: 8011285)
13. Chen YT, Old LJ. Cancer-testis antigens: targets for cancer immunotherapy. Cancer J Sci Am 1999; 5: 16-7. (PMID: 10188055)
14. Schoenberger SP, Sercarz EE. Harnessing self-reactivity in cancer immunotherapy. Semin Immunol 1996; 8: 303-309. (PMID: 8956459)
15. Johnston JV, Malacko AR, Mizuno MT, McGowan P, Hellstrom I, Hellstrom KE, Marquardt H, Chen L. B7-CD28 costimulation unveils the hierarchy of tumor epitopes recognized by major histocompatibility complex class I-restricted CD8+ cytolytic T lymphocytes. J Exp Med 1996; 183: 791-800. (PMID: 8642283)
16. Moore MW, Carbone FR, Bevan MJ. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 1988; 54: 777-785. (PMID: 3261634)
17. Rotzschke O, Falk K, Stevanovic S, Jung G, Walden P, Rammensee HG. Exact prediction of a natural T Cell epitope. Eur J Immunol 1991; 21: 2891-94 (PMID: 1718764)
18. Lipford GB, Hoffman M, Wagner H, Heeg K. Primary in vivo responses to OVA. Probing the predictive value of the Kb binding motif. J Immunol 1993; 150: 1212-22. (PMID: 7679422)
19. Porgador A, Snyder D, Gilboa E. Induction of antitumor immunity using bone marrow-generated dendritic cells. J Immunol 1996; 156: 2918-26. (PMID: 8609412)
20. Martinez-Kinader B, Lipford GB, Wagner H, Heeg K. Sensitization of MHC class I-restricted T cells to exogenous proteins: evidence for an alternative class I-restricted antigen presentation pathway. Immunology 1995; 86: 287-295. (PMID: 7490131)
21. el-Shami K, Tirosh B, Bar-Haim E, Carmon L, Vadai E, Fridkin M, Feldman M, Eisenbach L. MHC class I-restricted epitope spreading in the context of tumor rejection following vaccination with a single immunodominant CTL epitope. Eur J Immunol 1999; 29: 3295-3301. (PMID: 10540341)
22. Kim TS, Chung SW, Hwang SY. Augmentation of antitumor immunity by genetically engineered fibroblast cells to express both B7.1 and interleukin-7. Vaccine 2000; 18: 2886-94. (PMID: 10812232)
23. Hogquist KA, Jameson SC, Heath WR, Howard JL, Bevan MJ, Carbone FR. T cell receptor antagonist peptides induce positive selection. Cell 1994; 76: 17-27. (PMID: 8287475)
24. Kim SK, Reed DS, Heath WR, Carbone F, LeFrancois L. Activation and migration of CD8 T cells in the intestinal mucosa. J Immunol 1997; 159: 4295-4306. (PMID: 9379025)
25. Kim SK, Reed DS, Olson S, Schnell MJ, Rose JK, Morton PA, LeFrancois L. Generation of mucosal cytotoxic T cells against soluble protein by tissue-specific environmental and costimulatory signals. Proc Natl Acad Sci U S A 1998; 95: 10814-10819. (PMID: 9724787)
26. Lefrancois L, Altman JD, Williams K, Olson S. Soluble antigen and CD40 triggering are sufficient to induce primary and memory cytotoxic T cells. J Immunol 2000; 164: 725-32. (PMID: 10623816)
27. Minev BR, McFarland BJ, Spiess PJ, Rosenberg SA, Restifo NP. Insertion signal sequence fused to minimal peptides elicits specific CD8+ T-cell responses and prolongs survival of thymoma-bearing mice. Cancer Research 1994; 54: 4155-61. (PMID: 7518351)
28. Zhou F, Rouse BT, Huang L. Prolonged survival of thymoma-bearing mice after vaccination with a soluble protein antigen entrapped in liposomes: a model study. Cancer Research 1992; 52: 6287-91. (PMID: 1384958)
29. Newmaster RS, Mylin LM, Fu TM, Tevethia SS. Role of a subdominant H-2Kd-restricted SV40 tumor antigen cytotoxic T lymphocyte epitope in tumor rejection. Virology 1998; 244: 427-41. (PMID: 9601511)
30. Feltkamp MC, Vreugdenhil GR, Vierboom MP, Ras E, van der Burg SH, ter Schegget J, Melief CJ, Kast WM. Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors. Eur J Immunol 1995; 25: 2638-42. (PMID: 7589138)
31. van der Most RG, Murali-Krishna K, Whitton JL, Oseroff C, Alexander J, Southwood S, Sidney J, Chesnut RW, Sette A, Ahmed R. Identification of Db- and Kb-restricted subdominant cytotoxic T-cell responses in lymphocytic choriomeningitis virus-infected mice. Virology 1998; 240: 158-67. (PMID: 9448700)
32. Weidt G, Utermohlen O, Heukeshoven J, Lehmann-Grube F, Deppert W. Relationship among immunodominance of single CD8+ T cell epitopes, virus load, and kinetics of primary antiviral CTL response. J Immunol 1998; 160: 2923-31. (PMID: 9510196)
33. Fenton RG, Taub DD, Kwak LW, Smith MR, Longo DL. Cytotoxic T-cell response and in vivo protection against tumor cells harboring activated ras proto-oncogenes. J Natl Cancer Inst 1993; 85: 1294-02. (PMID: 8340941)
34. Brossart P, Goldrath AW, Butz EA, Martin S, Bevan MJ. Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. J Immunol 1997; 158: 3270-76. (PMID: 9120283)
35. Ferrone S, Marincola FM. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance [review]. Immunology Today 1995; 16: 487. (PMID: 7576053)
36. Marincola FM, Hijazi YM, Fetsch P, Salgaller ML, Rivoltini L, Cormier J, Simonis TB, Duray PH, Herlyn M, Kawakami Y, Rosenberg SA. Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions. J Immunother Emphasis Tumor Immunol 1996; 19: 192-205. (PMID: 8811494)
37. Chen Y, Stockert E, Tsang S, Coplan KA, Old LJ. Immunophenotyping of Melanomas for Tyrosinase: Implications for Vaccine Development. Proc Natl Acad Sci U S A 1995; 92: 8125-8129. (PMID: 7667256)
38. Ochsenbeing AF, Klenerman P, Karrer U, Ludewig B, Pericin M, Hengartner H, Zinkernagel RM. Immune surveillance against a solid tumor fails because of immunological ignorance. Proc Natl Acad Sci U S A 1999; 96: 2233-8. (PMID: 10051624)
39. Hermans IF, Daish A, Yang J, Ritchie DS, Ronchese F. Antigen expressed on tumor cells fails to elicit an immune response, even in the presence of increased numbers of tumor-specific cytotoxic T lymphocyte precursors. Cancer Res 1998; 58: 3909-17. (PMID: 9731502)
40. Mueller DL, Jenkins MK, Schwartz RH. Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy [review]. Ann Rev Imm 1989; 7: 445. (PMID: 2653373)
41. Staveley-O'Carroll K, Sotomayor E, Montgomery J, Borrello I, Hwang L, Fein S, Pardoll D, Levitsky H. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proc Natl Acad Sci U S A 1998; 95: 1178-1183. (PMID: 9448305)
42. Moskophidis D, Lechner F, Pircher H, Zinkernagel RM. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 1993; 362: 758-61. (PMID: 846928)
43. Kurts C, Kosaka H, Carbone FR, Miller JF, Heath WR. Class I-restricted cross-presentation of exogenous self-antigens leads to deletion of autoreactive CD8(+) T cells. J Exp Med 1997; 186: 239-45. (PMID: 9221753)
44. North RJ. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med 1982; 155: 1063-74. (PMID: 6460831)
45. Benacerraf B, Germain RN. A single major pathway of T-lymphocyte interactions in antigen-specific immune suppression. Scand J Immunol 1981; 13: 1-10. (PMID: 6972088)
46. Groux H, O'Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, Roncarolo MG. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997; 389: 737-742. (PMID: 9338786)
47. Bronte V, Wang M, Overwijk WW, Surman DR, Pericle F, Rosenberg SA, Restifo NP. Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells. J Immunol 1998; 161: 5313-20. (PMID: 9820504)
48. Speiser DE, Miranda R, Zakarian A, Bachmann MF, McKall-Faienza K, Odermatt B, Hanahan D, Zinkernagel RM, Ohashi PS. Self antigens expressed by solid tumors Do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J Exp Med 1997; 186: 645-53. (PMID: 9271580)
49. Srivastava PK. Do human cancers express shared protective antigens? or the necessity of remembrance of things past [review]. Semin Immunol 1996; 8: 295-302. (PMID: 8956458)
50. Nikolic-Zugic J, Bevan MJ. Role of self-peptides in positively selecting the T-cell repertoire. Nature 1990; 344: 65-7. (PMID: 2304556)
51. Kearney ER, Pape KA, Loh DY, Jenkins MK. Visualization of peptide-specific T cell immunity and peripheral tolerance induction in vivo. Immunity 1994; 1: 327-39. (PMID: 788941)